Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for Dextenza

americanpharmaceuticalreviewJuly 24, 2018

Tag: Ocular Therapeutix , FDA , NDA

PharmaSources Customer Service